Login to Your Account



In The Clinic NEWS

Cytokinetics Inc. is suspending development of its lead candidate, tirasemtiv, for ALS after it failed to hit both primary and secondary endpoints in a crucial phase III test.

HONG KONG – Kunshan Riboquark Pharmaceutical Technology Co. Ltd. enrolled the first patient in China for its global pivotal phase II/III study of ocular neuroprotectant candidate QPI-1007.

New frontier in genomics

As far as gene editing technologies go, clustered regularly interspaced short palindromic repeats, or CRISPR, tends to suck up all the oxygen in the room.

But so far, clinical gene editing has been achieved by another method.

More In The Clinic Headlines

Cast Your Vote

Should there be restrictions on the use of gene-editing technology?: